Table 1.

Correlation of adaptive immune responses to disruption of cerebral autoregulation while on ECMO (significance designated by *, bolded, and in red)

	ECMO patients - no injury			ECMO patients - brain injury
	% (R2)			% (R2)
Leukocyte population	D1	D3	D7	D1	D3	D7
General leukocytes	(−) 0.31	(−) 0.03	(−) 0.18	0.70*	0.71*	0.86
T cells	(−) 0.06	0.12	0.20	(−) 0.43	(−) 0.24	(−) 0.22
B cells	(−) 0.48	(−) 0.03	(−) 0.002	(−) 0.01	0.01	(−) 0.31
Activated B cells	0.03	0.45	0.34	(−) 0.16	0.55§	(−) 0.03
Helper T cells	0.10	0.17	0.009	(−) 0.58*	(−) 0.56	(−) 0.96
Activated helper T cells	(−) 0.43	(−) 0.30	(−) 0.56	0.75*	0.77**	0.99§
Cytotoxic T cells	0.009	(−) 0.12	0.002	0.58*	0.54§	0.88
Activated cytotoxic T cells	(−) 0.04	(−) 0.02	0.09	0.002	0.26	0.99*
Natural Killer T cells	0.55	(−) 0.008	0.19	0.43	0.26	0.70
Monocytes	0.04	(−) 0.04	(−) 0.53	(−) 0.16	(−) 0.10	0.65
Activated macrophages	0.0002	(−) 0.03	(−) 0.16	0.09	0.30	0.20
Dendritic cells	0.14	0.01	(−) 0.35	(−) 0.06	(−) 0.07	(−) 0.83
NK cells	(−) 0.01	(−) 0.02	(−) 0.007	(−) 0.19	(−) 0.15	(−) 0.37
Granulocytes	(−) 0.98**	0.35	0.93	(−) 0.24	(−) 0.21	(−) 0.99§
Patient number	(n=5)	(n=6)	(n=3)	(n=7)	(n=7)	(n=3)

R2= R square goodness of fit, linear regression; D, day; %, percent immune population; #, cell number/10ml; (−) negative slope in correlation

^*p<0.05

^**p<0.01

^§p<0.06